The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InGilead Sciences reported robust fourth-quarter earnings, surpassing consensus estimates for both EPS and revenue. This strong performance was primarily driven by its HIV prevention therapies and the successful launch of Yeztugo. However, the company's shares experienced a decline in pre-market trading after it issued weaker-than-expected fiscal 2026 guidance. Despite this cautious outlook, several prominent analysts, including Needham, Scotiabank, and Cantor Fitzgerald, reaffirmed their positive ratings. These firms also raised their price targets for Gilead, highlighting a divergence between the company's near-term performance and its future projections. The market reaction reflects a mixed sentiment, weighing strong current results against future uncertainties.